Ipilimumab vs Raltegravir Potassium
Ipilimumab vs Raltegravir Potassium: Overview
This comparison examines the pharmacological differences between Ipilimumab and Raltegravir Potassium.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Pharmacokinetics
Half-life: Ipilimumab — 14.7 days.
Chemical Properties
Type: Ipilimumab — Antibody; Raltegravir Potassium — Small molecule.